CME Group (CME) Aandelenoverzicht
CME Group Inc. exploiteert samen met haar dochterondernemingen contractmarkten voor de wereldwijde handel in futures en opties op futurescontracten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 3/6 |
Beloningen
Risicoanalyse
CME Community Fair Values
Create NarrativeSee what 83 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CME Group Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$290.12 |
| 52 Week Hoogtepunt | US$329.16 |
| 52 Week Laag | US$257.17 |
| Bèta | 0.26 |
| 1 maand verandering | 0.93% |
| 3 maanden verandering | -4.54% |
| 1 Jaar Verandering | 2.97% |
| 3 jaar verandering | 61.12% |
| 5 jaar verandering | 34.23% |
| Verandering sinds IPO | 3,281.35% |
Recent nieuws en updates
Recent updates
Narratiefupdate • May 15
CME: Mixed Street Views And New Markets Will Shape Future Earnings Power
Narrative Update on CME Group The analyst price target for CME Group has been trimmed by about $2, reflecting updated views on slightly softer revenue growth and a modestly lower future P/E multiple. At the same time, some analysts highlight areas of support such as commodities volumes as well as agriculture and prediction markets.Narratiefupdate • Apr 27
CME: Volatile Street Views And New Futures Will Shape Trading Mix
Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.Seeking Alpha • Apr 23
CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive
Summary CME Group delivered record Q1 volumes and revenue but missed consensus EPS and revenue estimates by narrow margins. CME remains a hold; the stock’s premium valuation already prices in strong volumes, steady cash flows, and its competitive moat. Growth is driven by diverse product expansion, including commodities, crypto, and cross-margining, but near-term upside is limited absent a volatility or trading surge. Key risks are volume normalization, regulatory changes, and tech disruptions; current price fairly reflects both strengths and risks. Read the full article on Seeking AlphaNarratiefupdate • Apr 11
CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes
The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.Narratiefupdate • Mar 26
CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix
Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.Narratiefupdate • Mar 11
CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook
Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.Narratiefupdate • Feb 25
CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook
The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.Narratiefupdate • Feb 10
CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook
The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.Narratiefupdate • Jan 27
CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook
The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.Narratiefupdate • Jan 12
CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook
Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.Narratiefupdate • Dec 27
CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks
Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.Narratiefupdate • Dec 13
CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility
Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.Narratiefupdate • Nov 16
CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead
The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.Seeking Alpha • Apr 27
CME: More Market Volatility Equals More Demands - Initiating With Strong Buy
Summary Initiating a 'Strong Buy' rating for CME with a fair value of $301 per share due to increased demand for hedging amid economic uncertainty and market volatility. CME's diverse product offerings and strong trading volume growth, particularly in interest rate options/futures, equity, FX, energy, and commodities, support its robust business model. CME's high operating margin, capex-light business model, and strategic use of Google Cloud enhance profitability and operational efficiency. Key risks include potential pushback on market data price increases and competition from FMX Futures Exchange in the US treasury market. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
CME Group At A New All-Time High - Valuation Concerns Justified?
Summary CME shares have delivered market-beating returns over the past two years, prompting the question of whether it's time to lock in profits. In this update, I discuss whether the rally appears sustainable against the backdrop of the 2024 results published in mid-February. The analysis focuses on average contract volumes and rates, signs of potential underinvestment given the surprisingly strong free cash flow, and includes an update on debt and leverage. I explain why I do not intend to sell my CME stock position despite the elevated valuation, and why I am not even considering a covered call strategy at this time. Read the full article on Seeking AlphaSeeking Alpha • Feb 18
CME Group: High Quality With Good Dividend Yield
Summary CME Group's near-monopoly in futures and options trading, with extraordinary 60% FCF margins, makes it a high-quality, capital-light business despite regulatory costs. Significant acquisitions like CBOT, NYMEX, and KCBT have solidified CME's market dominance, though future focus will be on dividends and smaller acquisitions. CME is slightly undervalued with a 4% dividend yield, making it a strong hold for dividend-focused investors seeking a high-quality business model. Read the full article on Seeking AlphaRendement voor aandeelhouders
| CME | US Capital Markets | US Markt | |
|---|---|---|---|
| 7D | -2.4% | -0.8% | -0.3% |
| 1Y | 3.0% | 9.8% | 26.7% |
Rendement versus industrie: CME presteerde slechter dan de US Capital Markets -sector, die het afgelopen jaar een rendement van 9.8 % opleverde.
Rendement versus markt: CME presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 26.7 % opleverde.
Prijsvolatiliteit
| CME volatility | |
|---|---|
| CME Average Weekly Movement | 3.7% |
| Capital Markets Industry Average Movement | 3.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: CME heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van CME is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1898 | 3,875 | Terry Duffy | www.cmegroup.com |
CME Group Inc. exploiteert samen met haar dochterondernemingen contractmarkten voor de wereldwijde handel in futures en opties op futurescontracten. Het biedt futures- en optieproducten aan op basis van rentetarieven, aandelenindexen en vreemde valuta; en landbouw-, energie- en metaalgrondstoffen, evenals diensten voor de handel in vastrentende waarden en vreemde valuta. Het bedrijf levert clearingdiensten, waaronder clearing, afwikkeling en garantie van futures- en optiecontracten, en geclearde swapproducten die via de beurzen worden verhandeld.
CME Group Inc. Samenvatting
| CME fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$109.57b |
| Inkomsten(TTM) | US$4.24b |
| Inkomsten(TTM) | US$6.74b |
24.8x
Koers/Winstverhouding15.6x
P/S-verhoudingIs CME overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CME resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$6.74b |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$6.74b |
| Overige uitgaven | US$2.50b |
| Inkomsten | US$4.24b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 11.71 |
| Brutomarge | 100.00% |
| Nettowinstmarge | 62.95% |
| Schuld/Eigen Vermogen Verhouding | 12.9% |
Hoe presteerde CME op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
3.9%
Huidig dividendrendement43%
UitbetalingsratioBetaalt CME een betrouwbaar dividend?
Zie CME dividendgeschiedenis en benchmarks| CME Group dividenddata | |
|---|---|
| Ex Dividend Datum | Jun 09 2026 |
| Betaaldatum dividend | Jun 25 2026 |
| Dagen tot Ex-dividend | 19 days |
| Dagen tot dividendbetaaldatum | 35 days |
Betaalt CME een betrouwbaar dividend?
Zie CME dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/20 05:20 |
| Aandelenkoers aan het einde van de dag | 2026/05/20 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
CME Group Inc. wordt gevolgd door 34 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Stephen Biggar | Argus Research Company |
| Benjamin Budish | Barclays |
| Roger Freeman | Barclays |